/NTHI
NTHI Stock - Neonc Technologies Holdings, Inc.
Healthcare|BiotechnologyNASDAQ
$7.01-0.14%
$0.01 (-0.14%) • Dec 19
42
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.29
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $7.71
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NTHI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$6.94 – $7.08
TARGET (TP)$8.06
STOP LOSS$6.45
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Key Metrics
Market CapN/A
P/E RatioN/A
Beta3.45
52W High$25.00
52W Low$3.20
Avg VolumeN/A
Income Statement (Fiscal Year)
Loading financial data...
Company Overview
Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
NTHILoading earnings data...
Latest News
NeOnc Technologies Announces Updated Results From Phase 1/2a And Compassionate-Use Experience Of NEO100; Says Updated Results Demonstrate Radiographic Remission In 6 Of 25 Patients
📈 PositiveBenzinga•Dec 15, 2025, 02:04 PM
NeOnc Technologies Q3 EPS $(0.45)
📉 NegativeBenzinga•Nov 14, 2025, 09:04 PM
NeOnc Technologies Completes Full Patient Enrollment In Ongoing NEO100-1 Phase 2a Clinical Trial
📈 PositiveBenzinga•Nov 13, 2025, 02:07 PM
NeOnc Announces Updated Clinical Results From Current Phase 1/2a And Compassionate Care Studies Involving Cohort Of 24 Patients With Recurrent WHO Grade III/IV IDH1–Mutant Astrocytoma Treated With NEO100
➖ NeutralBenzinga•Nov 12, 2025, 01:03 PM
NeOnc To Present Data Updates From Ongoing Phase 1/2a NEO100-1 Clinical Trial And Compassionate Use Program, Evaluating Intranasal Delivery Of NEO100 In Patients With Recurrent High Grade Malignant Glioma
📈 PositiveBenzinga•Nov 7, 2025, 02:09 PM
NeOnc Technologies Appoints President Amir Heshmatpour As CEO
➖ NeutralBenzinga•Nov 4, 2025, 02:01 PM
NeOnc Technologies' NuroMENA Signs A Master Services Agreement With Insights Research Organization And Solutions To Support NeOnc's CNS Cancer Therapy Programs
📈 PositiveBenzinga•Oct 9, 2025, 01:04 PM
NeOnc Technologies Clears UAE Approvals For $50M Quazar Partnership, Closing Mandated By October 23
📈 PositiveBenzinga•Oct 6, 2025, 01:03 PM
NeOnc Technologies shares are trading higher after the company announced it received FDA authorization to proceed with the Phase II trial of NEO212.
📈 PositiveBenzinga•Sep 10, 2025, 05:30 PM
FDA Authorizes NeOnc Technologies To Proceed With Phase IIa/IIb Of NEO212-01 Clinical Trial
📈 PositiveBenzinga•Sep 10, 2025, 01:07 PM
NeOnc Technologies Q2 EPS $(0.30) Down From $(0.27) YoY
📉 NegativeBenzinga•Aug 19, 2025, 01:22 PM
NeOnc Technologies signs agreement for $50M partnership with Quazar Investment
📈 PositiveSeeking Alpha•Jul 29, 2025, 01:23 PM
NeOnc board approves step toward $50M Quazar deal, MENA expansion; shares up 62%
📈 PositiveSeeking Alpha•Jul 10, 2025, 01:11 PM
NeOnc Technologies joins Russell Microcap Index
📈 PositiveSeeking Alpha•Jul 9, 2025, 01:19 PM
Frequently Asked Questions about NTHI
What is NTHI's current stock price?
Neonc Technologies Holdings, Inc. (NTHI) is currently trading at $7.01 per share. The stock has moved -0.14% today.
What is the analyst price target for NTHI?
No analyst price targets are currently available for this stock.
What sector is Neonc Technologies Holdings, Inc. in?
Neonc Technologies Holdings, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is NTHI's market cap?
Neonc Technologies Holdings, Inc. has a market capitalization of $0.14 billion, making it a small-cap company.
Does NTHI pay dividends?
No, Neonc Technologies Holdings, Inc. does not currently pay a dividend to shareholders.